The verdict
Our read at a glance.
Whether teduglutide's approved short bowel syndrome benefit supports the broader gut-healing or intestinal-repair claims sometimes attached to GLP-2 peptides.
- The signal
- Randomized trials in short bowel syndrome show teduglutide can reduce the volume of parenteral support some patients need by promoting intestinal absorptive surface. The evidence is specific to short bowel syndrome and to patients managed by specialists.
- The unknown
- Long-term neoplasia risk with continued use, durability of the reduction in parenteral support, and whether any of its intestinal-growth effect is relevant outside the approved population, which has not been shown.
- Our read
- A narrow, serious specialist drug, not a gut-health supplement. Teduglutide is genuinely approved for short bowel syndrome, but its mucosal-growth mechanism and neoplasia warnings make broad gut-repair claims both unsupported and a safety concern.
The mechanism
How it works.
Teduglutide is an analog of GLP-2, a hormone the gut releases to maintain its own lining, altered at one amino acid so it resists the enzyme that rapidly breaks down natural GLP-2. It activates GLP-2 receptors in the intestine, which increases blood flow and stimulates the absorptive lining to grow taller and expand its surface area. In short bowel syndrome that extra absorptive surface lets patients take up more nutrients and fluid, reducing how much intravenous feeding they need.
Safety & regulatory boundary
The consequential part.
Teduglutide labeling warns about the potential for neoplastic growth including colorectal polyps and cancer, intestinal obstruction, fluid overload, and biliary and pancreatic disease, and it requires monitoring such as colonoscopy. It is approved only for short bowel syndrome with parenteral dependence. Gattex and Revestive are the approved products and are not the same as compounded or research-labeled teduglutide, and the growth-promoting mechanism is a reason for caution rather than a general wellness benefit.
What's next
What we're watching.
Long-term safety registries, neoplasia surveillance data, and any studies testing GLP-2 biology outside short bowel syndrome.
Context
Why this is discussed.
Teduglutide is the clearest approved example of a GLP-2 analog, so it gets referenced in discussions of gut-repair peptides even though its approved use is a rare and serious condition.
The evidence base
21 cited references.
Regulatory & labels1
Takeda Pharmaceuticals America, Inc. (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-07-01
ClinicalTrials.gov · ACTIVE_NOT_RECRUITING · 2021-09-01
ClinicalTrials.gov · RECRUITING · 2026-03-05
ClinicalTrials.gov · NA · RECRUITING · 2024-10-30
ClinicalTrials.gov · RECRUITING · 2013-08-01
ClinicalTrials.gov · ACTIVE_NOT_RECRUITING · 2014-06-23
ClinicalTrials.gov · PHASE4 · COMPLETED · 2018-07-02
ClinicalTrials.gov · PHASE3 · RECRUITING · 2025-06-26
Indexed literature (PubMed)12
Pironi L · Nutr Clin Pract · 2023
Massironi S et al. · Dig Liver Dis · 2020
Wang SZ et al. · J Clin Med · 2025
Jeppesen PB et al. · Gastroenterology · 2012
Lenti MV et al. · United European Gastroenterol J · 2025
PubMed · 2006
Lenti MV et al. · United European Gastroenterol J · 2025
Sabra HK et al. · J Gastrointest Surg · 2024
Liu S et al. · Pak J Med Sci · 2025
Burgos Peláez R et al. · Nutr Hosp · 2016
Chiba M et al. · J Pediatr Gastroenterol Nutr · 2023
Naberhuis JK et al. · JPEN J Parenter Enteral Nutr · 2016
Keep reading